Your email has been successfully added to our mailing list.

×
0.00149175149175151 0.00149175149175151 0.000526500526500671 -0.00403650403650398 -0.0196560196560196 -0.0228150228150228 -0.0189540189540188 -0.0149157599157598
Stock impact report

Bioverativ Announces FDA Acceptance of Investigational New Drug Application for BIVV001 to Treat Hemophilia A

BIOVERATIV INC COMMON (BIVV) 
Last bioverativ inc common earnings: 2/13 04:15 pm Check Earnings Report
Company Research Source: Business Wire
BIVV001 is a novel, investigational factor VIII therapy designed to extend protection from bleeds with prophylaxis dosing of once weekly or longer On track to initiate a Phase 1/2a clinical trial in the second half of 2017 WALTHAM, Mass.--(BUSINESS WIRE)-- Bioverativ (NASDAQ: BIVV), a global biotechnology company focused on the discovery, development and commercialization of innovative therapies for hemophilia and other rare blood disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for BIVV001 (also known as rFVIIIFc-VWF-XTEN), a novel, investigational factor VIII therapy designed to potentially extend protection from bleeds with prophylaxis dosing of once weekly or longer for people with hemophilia A. “People with hemophilia A continue to have a strong unmet need f Show less Read more
Impact Snapshot
Event Time:
BIVV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BIVV alerts
Opt-in for
BIVV alerts

from News Quantified
Opt-in for
BIVV alerts

from News Quantified